ArticleStem cell research & therapy2026
iMSC-secreted factors preserve renal capillary networks and ameliorate fibrosis by interrupting the macrophage STING/CD8
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundRenal fibrosis, the common endpoint of chronic kidney disease, is exacerbated by renal ischemia. While human iPSC-derived MSCs (iMSCs) hold therapeutic promise, their role in modulating the ischemic renal microenvironment, particularly through macrophage-immune crosstalk, remains unclear. This study assesses whether iMSCs alleviate renal fibrosis by targeting macrophage-STING to restore capillaries.
methodsThe protective effects of iMSC-conditioned medium (iMSC-CM) were assessed in H₂O₂‑induced HK‑2 and HUVEC models using CCK‑8, ROS staining, scratch assay, and tube formation assays. A mouse model of unilateral ischemia‑reperfusion (UIR) was established; mice received intravenous iMSCs or PBS. Kidneys were analyzed by histology, immunohistochemistry, qPCR, and Western blot. Transcriptomic sequencing revealed enrichment of immune-related pathways, including the STING pathway. To validate the role of STING, UIR mice were treated with the STING agonist DMXAA with or without iMSCs, and STING activation was assessed in LPS-stimulated macrophages in vitro. Macrophage polarization was evaluated by F4/80 co‑staining with CD86 (M1) or CD206 (M2).
resultsiMSC-CM mitigated H₂O₂-induced damage in HK-2 cells by promoting proliferation, reducing ROS levels, and suppressing fibrosis markers, and it promoted repair and angiogenesis in HUVECs. In vivo, iMSCs homed to injured kidneys, attenuated inflammation and fibrosis, notably reduced capillary rarefaction. Mechanistically, iMSC treatment profoundly inhibited STING activation in renal macrophages. This suppression disrupted a critical inflammatory axis: it reduced macrophage-derived IFN-β, leading to decreased infiltration of cytotoxic CD8⁺ T cells, which are detrimental to vascular endothelial cells. Consequently, the renal capillary network was preserved. Finally, STING agonist treatment abolished the anti-fibrotic benefits of iMSCs.
conclusionCollectively, this work reveals that iMSCs ameliorate renal fibrosis via the macrophage STING/CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.